ClinicalTrials.gg
WithdrawnNCT06990776Updated Aug 3, 2025

A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects

A Phase 2 interventional study of TQA3605 tablets Placebo and TQA3605 Tablets in Chronic Hepatitis B, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Withdrawn at 29 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-08-03.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies in Hepatitis B, Chronic by Sino Biopharmaceutical Limited — 4 open to participants now, 6 under way, 1 of them phase 3. Hepatitis B, Chronic · Sino Biopharmaceutical Limited.

Enrollment
13th of 13
0 · median 116
Started
2025
the only one that year
Phase 2
4 of 13
1 open now
Registered
12th of 13
by date

Among the 13 studies in Hepatitis B, Chronic by Sino Biopharmaceutical Limited, this one is the 13th largest by enrollment, is the only one that started in 2025, is one of 4 in phase 2, and was the 12th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

4 of the 13 studies in Hepatitis B, Chronic by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Hepatitis B, Chronic by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled phase II study, in which all participants are required to use TQA3605 tablets/placebo in combination with entecavir. The purpose is to evaluate the efficacy and safety of TQA3605 tablets combined with entecavir in treatment-naive chronic HBV-infected subjects. A total of 215 subjects are required.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-65 years old (including boundary values), regardless of gender;
  • Screening requires virological , clinical or pathological evidence of virus infection for more than 6 months; HBsAg positive, HBeAg positive, ≤5× at screening;
  • Never received nucleoside (acid) analog or interferon treatment, or previously received no more than 12 weeks of treatment but had discontinued therapy at least 6 months prior to the screening visit;
  • Ability to communicate effectively with researchers and understand and comply with the requirements of this study, understand and sign the form;
  • Male subjects with female partners who have fertility or female subjects of childbearing age are willing to voluntarily adopt effective measures screening to within 3 months after leaving the group.

Exclusion criteria

Exclusion Criteria:

  • Pregnant (positive pregnancy test) or lactating women.
  • Co-infection with other viruses such as Hepatitis A Virus (HAV), Virus (HCV), Hepatitis D Virus (HDV), Hepatitis E Virus (HEV), (HIV), Syphilis, etc.;
  • History of cirrhosis or evidence of significant fibrosis or cirrhosis before or during screening;
  • History of hepatocellular carcinoma (HCC) or suspected HCC before or during screening.;
  • History of malignant tumors within the past 5 years prior to screening, except for certain cancers that can be completely cured by surgical resection;
  • Subjects with other chronic liver diseases, including but not limited to liver disease, alcoholic liver disease, Wilson's disease, Gilbert syndrome, etc;
  • Previous organ or bone marrow transplantation;
  • abnormal laboratory test results at screening.
  • Poorly controlled thyroid diseases or clinically significant thyroid dysfunction;
  • Autoimmune diseases;
  • Significant systemic or major illnesses other than liver disease.
  • Any systemic anti-tumor or therapy, or immunomodulatory therapy within 6 months prior to screening.
  • High-dose systemic use within 3 months prior to screening;
  • History of alcohol or drug abuse within the past year or excessive alcohol consumption.
  • History of blood transfusion within 2 months prior to screening;
  • History of allergy to drug or its .
  • Previously participated in the clinical trial of core protein allosteric modulators;
  • Participation in another clinical trial and receipt of an investigational drug within the following timeframes before the first dose in this study: 5 half-lives (if known) or twice the duration of the biological effect of the study treatment (if known), whichever is longer, or 90 days (if the half-life or duration is unknown);
  • History or condition of cardiovascular disease;
  • Any other condition deemed inappropriate for inclusion by the investigator.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    100mg TQA3605 tablets + entecavir (ETV) (PART A)

    Patients aged 30-65 years old group:TQA3605 tablets, 100mg once a day, orally for 48 weeks in combination with entecavir, followed by treatment with entecavir for 24 weeks

    Drug: TQA3605 Tablets · Drug: Entecavir dispersible tablets

  • Experimental
    200mg TQA3605 tablets +ETV (PART A)

    Patients aged 30-65 years old group:TQA3605 tablets, 200mg once a day, orally for 48 weeks in combination with entecavir, followed by treatment with entecavir for 24 weeks

    Drug: TQA3605 Tablets · Drug: Entecavir dispersible tablets

  • Placebo comparator
    TQA3605 tablets Placebo +ETV (PART A)

    Patients aged 30-65 years old group: TQA3605 tablets placebo, once a day, orally for 48 weeks in combination with entecavir, followed by treatment with entecavir for 24 weeks.

    Drug: TQA3605 tablets Placebo

  • Experimental
    200mg TQA3605 tablets +ETV (PART B)

    Patients aged 18-30 years old group:TQA3605 tablets, 200mg once a day, orally for 48 weeks in combination with entecavir, followed by treatment with entecavir for 24 weeks.

    Drug: TQA3605 Tablets · Drug: Entecavir dispersible tablets

  • Placebo comparator
    TQA3605 tablets Placebo +ETV (PART B)

    Patients aged 18-30 years old group:TQA3605 tablets Placebo taken once a day, orally for 48 weeks in combination with entecavir, followed by treatment with entecavir for 24 weeks.

    Drug: TQA3605 tablets Placebo

Interventions

  • DrugTQA3605 tablets Placebo

    Placebo contains no active substance.

  • TQA3605 tablets is core protein allosteric modulators

  • Entecavir dispersible tablets is an inhibitor of hepatitis B virus replication.

06

What researchers measure

Primary outcomes

  1. hepatitis B virus (HBV) DNA <10 IU/mL

    Percentage of subjects with HBV DNA below the lower limit of quantification (\<10 IU/mL) after 48 weeks of treatment.

    Time frame: 48 weeks

Secondary outcomes

  1. Percentage of subjects with HBV DNA<10 IU/mL

    Percentage of subjects with HBV DNA\<10 IU/mL at week 12, 24, 36, 60, and 72

    Time frame: 12 weeks, 24 weeks, 36 weeks, 60 weeks, 72 weeks

  2. Percentage of HBV DNA<20 IU/mL

    Percentage of subjects with HBV DNA\<20 IU/mL at weeks 12, 24, 36, 48, 60, and 72 of treatment.

    Time frame: 12 weeks, 24 weeks, 36 weeks, 48weeks, 60 weeks, 72 weeks

  3. Percentage of subjects with HBeAg serologic clearance and/or serologic conversion

    Percentage of subjects with HBeAg serologic clearance and/or serologic conversion

    Time frame: 24weeks, 48 weeks, 72 weeks

  4. Alanine aminotransferase(ALT)≤The upper limit of the normal reference value (ULN)

    The rate of ALT normalization at weeks 24, 48, and 72 of treatment

    Time frame: 24weeks, 48 weeks, 72 weeks

  5. Virology breakthrough percentage

    Percentage of subjects who experienced virological breakthroughs at weeks 24, 48, and 72 of treatment

    Time frame: 24weeks, 48 weeks, 72 weeks

  6. Actual values of HBV markers and changes over time relative to baseline

    Actual values of HBsAg, HBeAg, HBV DNA, HBV RNA, and Hepatitis B core-related antigen (HBcrAg) at each visit time point and their changes over time relative to baseline.

    Time frame: 12 weeks, 24 weeks, 36 weeks, 48 weeks, 72 weeks

  7. Adverse events (AE)

    The incidence and severity of adverse events.

    Time frame: 72 weeks

  8. Steady state minimum concentration (Cmin,ss)

    Cmin,ss of TQA3605 and its metabolite

    Time frame: 48 weeks

07

Study locations

29 sites
  • Beijing Ditan Hospital Capital Medical University
    Beijing, Beijing Municipality 100015, China
  • Beijing Youan Hospital,Capital Medical University
    Beijing, Beijing Municipality 100069, China
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing Municipality 400010, China
  • The Southwest Hospital of AMU
    Chongqing, Chongqing Municipality 400038, China
  • Mengchao Hepatobiliary Hospital of Fujian Medical University
    Fuzhou, Fujian 350025, China
  • NanFang Hospital
    Guangzhou, Guangdong 510515, China
  • Peking University Shenzhen Hospital
    Shenzhen, Guangdong 518036, China
  • The First Affiliated Hospital of GUANGXI Medical University
    Nanning, Guangxi 530021, China
  • Hebei Medical University Third Hospital
    Shijiazhuang, Hebei 050000, China
  • Zhengzhou No.6 peoples Hospital
    Zhengzhou, Henan 450000, China
  • Henan Provincial People's Hospital
    Zhengzhou, Henan 450002, China
  • The First Hospital of Changsha
    Changsha, Hunan 410005, China
  • Jiangsu Provincial People's Hospital
    Nanjing, Jiangsu 210003, China
  • The Second Hospital of Nanjing
    Nanjing, Jiangsu 210003, China
  • Naniing Drum Tower Hospital
    Nanjing, Jiangsu 210008, China
  • The Fifth People's Hospital of Suzhou
    Suzhou, Jiangsu 215131, China
  • The Fifth People's Hospital of Wuxi
    Wuxi, Jiangsu 214061, China
  • Zhenjiang Third People's Hospital
    Zhenjiang, Jiangsu 212004, China
  • The First Affiliated Hospital of Nanchang University
    Nanchang, Jiangxi 330000, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • Shengjing Hospital Affiliated to China Medical University
    Shenyang, Liaoning Liaoning, China
  • The First Affiliated Hospital of Xi'an Jiao Tong University
    Xi'an, Shaanxi 710000, China
  • Xi'an Jiaotong University Second Affiliated Hospital
    Xi'an, Shaanxi 710000, China
  • The Second Hospital of Shandong University
    Jinan, Shandong 250033, China
  • Shandong Provincial Clinical Center for Public Health
    Jinan, Shandong 250102, China
  • Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
    Shanghai, Shanghai Municipality 200000, China
  • Shanghai Tongren Hospital
    Shanghai, Shanghai Municipality 200336, China
  • The First Affiliated Hospital of Xinjiang Medical University
    Ürümqi, Xinjiang 830013, China
  • Yiwu Central Hospital
    Yiwu, Zhejiang 322099, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2025 to primary completion in Jul 2025, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2025
First posted
May 25, 2025
StartActual
Jul 9, 2025
Primary completionActual
Jul 17, 2025
CompletionActual
Jul 17, 2025
Last update
Aug 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06990776
Responsible party
Sponsor
First posted
May 25, 2025
Start date
Jul 9, 2025
Primary completion
Jul 17, 2025
Completion
Jul 17, 2025
Last update
Aug 3, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQA3605

Start the discussion